Stepan Company (SCL) Q3 2025 earnings summary

Executive summary

• Q3 2025 net income was $10.8 million, down 54% year-over-year, mainly due to a higher effective tax rate and increased interest expense; adjusted net income was $10.9 million.

• Adjusted EBITDA for Q3 2025 was $56.2 million, up 6% year-over-year, driven by Specialty Products and Crop Productivity, despite higher raw material and start-up costs at the Pasadena facility.

• Net sales rose 8% to $590.3 million, with global sales volume up 1% year-over-year, supported by higher average selling prices and favorable foreign currency translation.

• Free cash flow improved to $40.2 million, up from negative $4.0 million in the prior year, driven by reductions in working capital.

• Pasadena, Texas alkoxylation facility ramped up production, incurring $8.6 million in start-up costs; sale of Philippines assets expected to close in Q4 2025.

Financial highlights

• Q3 2025 net income: $10.8 million ($0.47 per share); adjusted net income: $10.9 million ($0.48 per share), both down 54% year-over-year.

• Q3 2025 adjusted EBITDA: $56.2 million, up 6% year-over-year.

• Q3 2025 net sales: $590.3 million (+8% YoY); gross profit: $71.0 million (down from $75.7 million YoY).

• Cash from operations was $69.8 million for the quarter; cash and cash equivalents at quarter end: $118.5 million.

• Free cash flow for Q3 was $40.2 million; net debt at September 30, 2025: $537 million; net debt ratio: 30%.

Outlook and guidance

• Full-year 2025 adjusted EBITDA growth and positive free cash flow are anticipated.

• Capital expenditures for 2025 are forecasted at $118–123 million; debt repayments planned at $69 million.

• Margin recovery in surfactants expected to continue into 2026 as raw material prices normalize; Pasadena facility to reach full contribution in 2026.

• Management expects improving Polymer demand if interest rates decline and construction activity rebounds.

• Effective tax rate expected to normalize at 24–26% due to new US tax legislation and lower R&D credits.